Drug Profile
GBT 009
Alternative Names: GBT009Latest Information Update: 12 Sep 2015
Price :
$50
*
At a glance
- Originator Garnet BioTherapeutics
- Class Cell therapies
- Mechanism of Action Cytokine stimulants; Intercellular signalling peptide and protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Scars
Most Recent Events
- 12 Sep 2015 No recent reports of development identified - Phase-II for Scars (Prevention) in USA (Intradermal)
- 28 Jan 2015 Garnet BioTherapeutics filed a friend of the court (amicus) brief at the Federal Circuit to protect its rights against Athersys in a patent interference
- 26 Sep 2014 Garnet BioTherapeutics receives patent allowance for Cell Populations Which Co-Express CD49c and CD90 in USA